HOME >> BIOLOGY >> NEWS
New data suggest anakinra may accelerate reduction in joint destruction and improve quality of life for rheumatoid arthritis patients

PHILADELPHIA, Pa., October 29, 2000 - Amgen (NASDAQ: AMGN) today announced that anakinra or interleukin-1 receptor antagonist (IL-1ra), an investigational rheumatoid arthritis (RA) therapy not yet approved by the U.S. Food and Drug Administration, may accelerate reduction in joint damage progression and improvement in the health-related quality of life for RA patients, according to results of several studies presented this week at the American College of Rheumatology (ACR) annual meeting.

Bone and Joint Data

In a double-blind, multicenter study, 472 patients were randomized to receive 30 mg, 75 mg or 150 mg daily treatment or placebo. After 6 months, the placebo patients were re-randomized to treatment with one of the anakinra doses. The patients were evaluated by radiographs using a modified Sharp assessment tool, which measures joint destruction based on erosive damage and joint space narrowing of the hand and wrist. The sum of these two subscales provides the total Sharp score. Increases in scores signify progressive structural destruction.

In the first analysis, patients treated with anakinra for a full year experienced an accelerated slowing of joint destruction in the second 6-month period relative to the significant improvements in the first 6 months of treatment. After six months, anakinra-treated patients experienced nearly twice the rate of reduction in joint destruction as the placebo group (increase in Sharp score of 1.86 vs. 3.61, respectively, p=0.002). After an additional six months of therapy, patients on anakinra experienced an increase of 1.18 compared with 1.32 in the placebo group (p<0.001). This accelerated improvement in benefit was seen at both 75 and 150 mg doses.

"Not only did patients on anakinra see benefits as early as six months on treatment, but the longer they were on therapy, the more improvement they experienced," said co-author Dr. Barry Bresnihan, professor of rheumatology, University Col
'"/>

Contact: Rebecca Hamm, Amgen
rhamm@amgen.com
805-447-3872
Porter Novelli
28-Sep-2000


Page: 1 2 3 4 5

Related biology news :

1. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
2. Research suggests new avenue for stopping, preventing colon cancer
3. New sign language suggests children create languages fundamentals through learning
4. Images of tail of protein needed for cell multiplication suggest anticancer drug targets
5. New research suggests early diet may play key role in protecting against childhood leukaemia
6. Serotonin metabolites in mollusks suggest pathways for human therapies
7. New research suggests link between maternal diet and childhood leukemia risk
8. Research suggests unborn children may be at risk from environmental pollution
9. Study suggests cell-cycle triggers might be cancer drug targets
10. Computer imaging of Archeopteryx skull suggests this dinosaur-bird link could fly
11. Study suggests humans can speed evolution

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/5/2019)... ... March 05, 2019 , ... Join this live ... metadata-driven approach will help data analysts and bioinformaticians focus on data analysis without worrying ... that can come from different source systems. Some sources of data include:, ...
(Date:2/27/2019)... ... February 27, 2019 , ... Fluxion Biosciences, a leading developer of precision solutions ... Cancer Institute grant for further development of its ERASE-Seq liquid biopsy technology. The Phase ... lab of Dr. Omar Mian at the Cleveland Clinic. , Liquid biopsies offer the ...
(Date:2/22/2019)... ... February 20, 2019 , ... ... plans today to expand the company’s footprint in Frederick, MD after a year ... used RoosterBio’s adult human mesenchymal stem/stromal cell (hMSCs) products to streamline their product ...
Breaking Biology News(10 mins):
(Date:3/9/2019)... DIEGO (PRWEB) , ... March 07, 2019 , ... ... Technologies, is a pioneer in the development and commercialization of high performance, cutting-edge ... PhysioStim, a leading European CRO with GLP-certified expertise in cardiovascular pharmacology and electrophysiology, ...
(Date:3/5/2019)... Texas (PRWEB) , ... March 05, 2019 , ... ... a biopharmaceutical cold chain engineering firm with regulatory filing authorities, logistics network experts, ... corporate information to initiate its participation in the Inc. Verified Profile program, Inc. ...
(Date:2/27/2019)... ... February 26, 2019 , ... Superior Controls, Inc., a leading ... 140 employees on both the east and west coasts, today announced that employee ... New Hampshire. Sandmaier, a senior project engineer, joins Taggart McCormick, P.E., Anthony Whitesell, ...
(Date:2/22/2019)... ... February 20, 2019 , ... Superior Controls, Inc. ... solutions with 140 employees on both the east and west coasts, today announced the ... working out of the company’s Seabrook, New Hampshire office. In his new role, ...
Breaking Biology Technology:
Cached News: